A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients

Cancer Science

Volumn 101, Issue 10, 2010, Pages 2227-2233

  Ishiguro, Takahiro ^a   Kawai, Shigeto ^a   Habu, Kiyoshi ^a   Sugimoto, Masamichi ^a   Shiraiwa, Hirotake ^a   Iijima, Shigeyuki ^a   Ozakis, Shuji ^b   Matsumoto, Toshio ^b   Yamada Okabe, Hisafumi ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE LINKED OLIGOSACCHARIDE; FUCOSYLTRANSFERASE; GUANOSINE DIPHOSPHATE FUCOSE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; UNCLASSIFIED DRUG; BST2 PROTEIN, HUMAN; GLUCOSE TRANSPORTER; GLUCOSYLTRANSFERASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; SLC35C1 PROTEIN, HUMAN;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER PATIENT; DRUG POTENCY; FERMENTATION; GENE DISRUPTION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; ANIMAL; CHO CELL LINE; CRICETULUS; HAMSTER; IMMUNOLOGY; MULTIPLE MYELOMA; PHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; CHO CELLS; CRICETINAE; CRICETULUS; GLUCOSYLTRANSFERASES; GPI-LINKED PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MONOSACCHARIDE TRANSPORT PROTEINS; MULTIPLE MYELOMA;

EID: 77957094316     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01663.x     Document Type: Article

References (33)

1. Laubach JP, Mahindra A, Mitsiades CS. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009, 23:2222-32.
2. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009, 145:681-708.
3. Mitsiades CS, Hideshima T, Chauhan D. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009, 46:166-75.
4. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373:1033-40.
5. Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 1997, 90:3179-86.
6. Ozaki S, Kosaka M, Wakahara Y. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999, 93:3922-30.
7. Ono K, Ohtomo T, Yoshida K. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol Immunol 1999, 36:387-95.
8. Kawai S, Koishihara Y, Iida S. Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24. Leuk Res 2006, 30:949-56.
9. Kawai S, Yoshimura Y, Iida S. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol Rep 2006, 15:361-7.
10. Preithner S, Elm S, Lippold S. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 2006, 43:1183-93.
11. Iida S, Misaka H, Inoue M. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 2006, 12:2879-87.
12. Shields RL, Lai J, Keck R. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277:26733-40.
13. Ripka J, Adamany A, Stanley P. Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose. Arch Biochem Biophys 1986, 249:533-45.
14. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004, 87:614-22.
15. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 2004, 88:901-8.
16. Kanda Y, Imai-Nishiya H, Kuni-Kamochi R. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. J Biotechnol 2007, 130:300-10.
17. Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 2006, 93:851-61.
18. Lazar GA, Dang W, Karki S. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006, 103:4005-10.
19. Stavenhagen JB, Gorlatov S, Tuaillon N. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007, 67:8882-90.
20. Yagi T, Ikawa Y, Yoshida K. Homologous recombination at c-fyn locus of mouse embryonic stem cells with use of diphtheria toxin A-fragment gene in negative selection. Proc Natl Acad Sci U S A 1990, 87:9918-22.
21. Boer PH, Potten H, Adra CN, Jardine K, Mullhofer G, McBurney MW. Polymorphisms in the coding and noncoding regions of murine Pgk-1 alleles. Biochem Genet 1990, 28:299-308.
22. Bigge JC, Patel TP, Bruce JA, Goulding PN, Charles SM, Parekh RB. Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Anal Biochem 1995, 230:229-38.
23. Cartron G, Dacheux L, Salles G. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-8.
24. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-7.
25. Musolino A, Naldi N, Bortesi B. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-96.
26. Bibeau F, Lopez-Crapez E, Di Fiore F. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27:1122-9.
27. Zhang W, Gordon M, Schultheis AM. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-8.
28. Ferrara C, Stuart F, Sondermann P, Brünker P, Umaña P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006, 281:5032-6.
29. Shinkawa T, Nakamura K, Yamane N. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003, 278:3466-73.
30. Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev 2008, 224:85-97.
31. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006, 20:732-3.
32. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-3.
33. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-30.